Jefferson Health

Physician Profile

Matthew Carabasi, MD

Jefferson University Physician

Academic Title: Professor

Specialties
Hematology - Medical Oncology
Medical Oncology
Medical Oncology - Bone Marrow Transplant
Medical Oncology - Hematologic Malignancies
Medical Oncology - Leukemia/Lymphoma

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
925 Chestnut Street
Suite 420A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-2340

Medical Services

Board Certifications

  • Internal Medicine
  • Medical Oncology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2016,2015,2014,2013,2012,2011,2010

Notes

Dr. Carabasi also specializes in stem cell transplantation.

Education

  • Jefferson Medical College, Medical School

Internship

  • Hahnemann University Hospital

Residency

  • Hahnemann University Hospital

Fellowship

  • Memorial Sloan-Kettering Cancer Center, NY

Recent Publications

Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization

A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation

A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease

Clostridium difficile colonization and disease in patients undergoing hematopoietic stem cell transplantation

No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation

Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia

A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing

Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: How much progress has been made?

Adenovirus DNA polymerase is recognized by human CD8+ T cells

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

Marrow ablative chemotherapy with hematopoietic stem cell rescue

Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen

Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations

Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse

Fatal sickle cell crisis after granulocyte colony-stimulating factor administration [1]

T cell depleted allogeneic PBSC transplantation using CD34+ cell selection

NCCN Practice Guidelines for Acute Myelogenous Leukemia.

A phase I-II trial to examine the toxicity of CMV- and EVB-specific cytotoxic T lymphocytes when used for prophylaxis against EVB and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants

T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease